$4.07
-0.15 (-3.44%)
Open$4.24
Previous Close$4.22
Day High$4.34
Day Low$3.90
52W High$11.88
52W Low$2.14
Volume—
Avg Volume73.4K
Market Cap94.62M
P/E Ratio—
EPS$-2.21
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+462.4% upside
Current
$4.07
$4.07
Target
$22.89
$22.89
$19.41
$22.89 avg
$38.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.76M | 20.47M | 20.59M |
| Net Income | 3.46M | 2.44M | 2.89M |
| Profit Margin | 15.9% | 11.9% | 14.1% |
| EBITDA | 6.13M | 5.18M | 5.24M |
| Free Cash Flow | 2.45M | 2.75M | 2.72M |
| Rev Growth | +16.8% | +12.7% | +4.6% |
| Debt/Equity | 0.77 | 0.70 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |